SymBio Pharmaceuticals Limited
Initiation of Consultations for Conditional Marketing Authorization (CMA) in the UK for Brincidofovir (BCV)
Consultations with the MHRA have begun for BCV to obtain UK CMA. The company will concurrently complete the global Phase III trial as quickly as possible to accelerate access to global markets. Impact on the fiscal year ending December 2026 consolidated results is unknown/not disclosed.
Key Figures
- Number of enrolled patients as of 2026/9/17: 30 patients
- Enrollment targets: 69 patients by end of 2026, 180 patients by end of 2027
- Current impact: Impact on consolidated earnings guidance is Unknown
AI要約
Key Points
SymBio Pharmaceuticals has initiated consultations with the UK MHRA for obtaining Conditional Marketing Authorization (CMA) for Brincidofovir (BCV). CMA is a system that allows earlier market access for patients with serious unmet needs, and the company plans to proceed in parallel with completing the ongoing global Phase III clinical trial. Through dialogue with regulatory authorities, the company aims for expedited market access when clinical benefit is judged to outweigh risks despite some data uncertainty. Impact on consolidated results for the fiscal year ending December 2026 has not been disclosed.
Outlook and Strategy
The company is pursuing a strategy to accelerate global expansion of BCV across three therapeutic areas (post-transplant viral infections, oncology, and neurological disorders). By securing early market access via CMA while completing the ongoing global Phase III trial and strengthening collaboration with regulatory authorities, the company aims to shorten the lead time to market launch.
SymBio Pharmaceuticals Limited
Company overview · Stock price · Financial data · All IR
